Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Yamazaki

Showing results (61-70 of 252) with videos related to

Pageof 26
Sort By:
Anticancer Research|September 10, 2014
Phase I study of Efatutazone, an oral PPARγ agonist, in patients with metastatic solid tumorsHaruyasu Murakami, Akira Ono, Toshiaki Takahashi, et al.
Japanese Journal of Clinical Oncology|July 27, 2010
Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective studyTakehito Shukuya, Hirofumi Yasui, Narikazu Boku, et al.
World Journal of Surgery|December 14, 2019
The Safety and Survival Outcome of Hepatectomy with Combined Bile Duct Resection for Colorectal Liver MetastasisTakaaki Ito, Teiichi Sugiura, Yukiyasu Okamura, et al.
Brain Tumor Pathology|February 24, 2011
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencingShingo Takano, Wei Tian, Masahide Matsuda, et al.
Japanese Journal of Clinical Oncology|July 7, 2010
Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancerShuichi Hironaka, Kentaro Yamazaki, Keisei Taku, et al.
Japanese Journal of Clinical Oncology|May 1, 2009
Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatinHirofumi Yasui, Takayuki Yoshino, Narikazu Boku, et al.
Cancer Chemotherapy and Pharmacology|May 4, 2023
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumorsNoboru Yamamoto, Takafumi Koyama, Toshio Shimizu, et al.
Cancer Chemotherapy and Pharmacology|July 26, 2014
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumorsToshihiko Doi, Yusuke Onozawa, Nozomu Fuse, et al.
Investigational New Drugs|December 17, 2013
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancerYoshito Komatsu, Takayuki Yoshino, Kentaro Yamazaki, et al.
BMC Cancer|January 20, 2023
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorinTakeshi Kawakami, Akiko Todaka, Kotoe Oshima, et al.
Pageof 26

Showing results (61-70 of 252) with videos related to

Sort By:
Pageof 26
Anticancer Research|September 10, 2014
Phase I study of Efatutazone, an oral PPARγ agonist, in patients with metastatic solid tumorsHaruyasu Murakami, Akira Ono, Toshiaki Takahashi, et al.
Japanese Journal of Clinical Oncology|July 27, 2010
Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective studyTakehito Shukuya, Hirofumi Yasui, Narikazu Boku, et al.
World Journal of Surgery|December 14, 2019
The Safety and Survival Outcome of Hepatectomy with Combined Bile Duct Resection for Colorectal Liver MetastasisTakaaki Ito, Teiichi Sugiura, Yukiyasu Okamura, et al.
Brain Tumor Pathology|February 24, 2011
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencingShingo Takano, Wei Tian, Masahide Matsuda, et al.
Japanese Journal of Clinical Oncology|July 7, 2010
Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancerShuichi Hironaka, Kentaro Yamazaki, Keisei Taku, et al.
Japanese Journal of Clinical Oncology|May 1, 2009
Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatinHirofumi Yasui, Takayuki Yoshino, Narikazu Boku, et al.
Cancer Chemotherapy and Pharmacology|May 4, 2023
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumorsNoboru Yamamoto, Takafumi Koyama, Toshio Shimizu, et al.
Cancer Chemotherapy and Pharmacology|July 26, 2014
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumorsToshihiko Doi, Yusuke Onozawa, Nozomu Fuse, et al.
Investigational New Drugs|December 17, 2013
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancerYoshito Komatsu, Takayuki Yoshino, Kentaro Yamazaki, et al.
BMC Cancer|January 20, 2023
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorinTakeshi Kawakami, Akiko Todaka, Kotoe Oshima, et al.
Pageof 26